Joseph Oliveto Biography and Net Worth

President and Chief Executive Officer of Milestone Pharmaceuticals

Mr. Oliveto has served as Milestone’s President and Chief Executive Officer since March 2017 and as a member of Milestone’s board of directors since July 2017. Prior to Milestone Pharmaceuticals, Mr. Oliveto was President, CEO and a Director of Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) where he led the company through a successful turnaround that included an NDA filing for, and FDA approval of, Northera™, a drug for the treatment of Neurogenic Orthostatic Hypotension, and the subsequent sale of Chelsea to Lundbeck, Inc. Mr. Oliveto joined Chelsea in 2008 following a two-year assignment as an Executive in Residence at Pappas Ventures, a life sciences venture capital firm, where he advised portfolio companies on strategy and governance. Prior to Pappas Ventures, Mr. Oliveto served in a number of progressively senior positions across several operating areas over an 18 year career at Hoffmann-La Roche Inc., including as a Global Alliance Director for Roche’s partnering organization. During his tenure, he played an integral part in the success of multiple NDA approvals, comprehensive launch programs, and licensing transactions. Joe also serves as an active member of the NC Biotech Center’s Greater Charlotte Advisory Committee.

Mr. Oliveto received a BA in Chemistry and an MBA from Rutgers University.

What is Joseph Oliveto's net worth?: The estimated net worth of Joseph Oliveto is at least $560.04 thousand as of April 16th, 2026. Mr. Oliveto owns 446,244 shares of Milestone Pharmaceuticals stock worth more than $560,036 as of August 10th. This net worth estimate does not reflect any other assets that Mr. Oliveto may own. Learn More about Joseph Oliveto's net worth.
How do I contact Joseph Oliveto?: The corporate mailing address for Mr. Oliveto and other Milestone Pharmaceuticals executives is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. Milestone Pharmaceuticals can also be reached via phone at (514) 336-0444 and via email at [email protected]. Learn More on Joseph Oliveto's contact information.
Has Joseph Oliveto been buying or selling shares of Milestone Pharmaceuticals?: Joseph Oliveto has not been actively trading shares of Milestone Pharmaceuticals within the last three months. Most recently, Joseph Oliveto sold 36,500 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a transaction totalling $82,490.00. Following the completion of the sale, the chief executive officer now directly owns 446,244 shares of the company's stock, valued at $1,008,511.44. Learn More on Joseph Oliveto's trading history.
Who are Milestone Pharmaceuticals' active insiders?: Milestone Pharmaceuticals' insider roster includes David Bharucha (Chief Medical Officer), Jeffrey Nelson (Chief Operating Officer), and Joseph Oliveto (President and Chief Executive Officer). Learn More on Milestone Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Milestone Pharmaceuticals?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 452,827 shares worth more than $1,017,948.37. The most recent insider tranaction occured on April, 16th when CEO Joseph Oliveto sold 36,500 shares worth more than $82,490.00. Insiders at Milestone Pharmaceuticals own 5.0% of the company. Learn More about insider trades at Milestone Pharmaceuticals.
Information on this page was last updated on 4/16/2026.

Joseph Oliveto Insider Trading History at Milestone Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2026	Sell	36,500	$2.26	$82,490.00	446,244
1/26/2026	Sell	34,523	$1.93	$66,629.39	482,744
1/8/2026	Sell	43,000	$2.25	$96,750.00	303,721
1/7/2026	Sell	500	$2.25	$1,125.00	346,721
12/15/2025	Sell	133,054	$2.32	$308,685.28	450,667

Joseph Oliveto Buying and Selling Activity at Milestone Pharmaceuticals

Milestone Pharmaceuticals Company Overview

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Today's Range

Now: $1.27

$1.20

$1.28

50 Day Range

MA: $1.24

$1.04

$1.36

2 Week Range

Now: $1.27

$1.00

$3.06

Volume

1,342,655 shs

Average Volume

1,872,258 shs

Market Capitalization

$157.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98